Anti-Mouse RANKL (CD254) – Biotin
Anti-Mouse RANKL (CD254) – Biotin
Product No.: R1355
- -
- -
Clone IK22/5 Target RANKL Formats AvailableView All Product Type Monoclonal Antibody Alternate Names CD254, TRANCE, hRANKL2, sOdf, TNF-Related Activation-Induced Cytokine [TRANCE], Osteoprotegrin Ligan Isotype IgG2a κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Immunogen Purified Recombinant Mouse RANKL (>98%) Product Concentration 0.5 mg/ml Formulation This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2831712 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for RANKL antibody, clone IK22/5 for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100 μl of whole blood. Titration of the reagent is recommended for optimal performance for each application. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone IK22/5 recognizes an epitope on mouse RANKL. Background RANKL antibody, clone IK22/5, recognizes receptor activator of NF-κB ligand (RANKL), also known as CD254, TNF-related activation-induced cytokine (TRANCE), tumor necrosis factor ligand superfamily member 11 (TNFSF11), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF). RANKL is a type II transmembrane protein belonging to the TNF cytokine superfamily and binds to the signaling receptor, RANK, or decoy receptor, osteoprotegerin (OPG). RANKL is expressed on osteoclasts and is essential for osteoclast differentiation, activation, and survival1. RANKL is also expressed on activated T cells and regulates T cell-dendritic cell (DC) interactions, enhancing DC activation and survival2-3. In addition, RANKL is crucial for lymph node, bone marrow, and thymus development4. Treatment with denosumab, an antibody directed against RANKL, is approved for the treatment of patients at high risk for bone fractures, including osteoporosis, and has shown anti-tumor effects5.
Antigen Distribution RANKL is expressed on activated T cells and osteoclasts. Ligand/Receptor RANK, OPG PubMed NCBI Gene Bank ID UniProt.org Research Area Cell Biology . Immunology References & Citations1. Park JH, et al. (2017) Mol Cells. 40(10):706-713 2. Wong BR, et al. (1997) J Biol Chem. 272(40):25190-4 3. Anderson, D. M., et al. (1997) Nature 390:175. 4. Ono T, et al. (2020) Inflamm Regen. 2020;40:2. 5. de Groot AF, at al. (2018) Cancer Treat Rev. 62:18-28 Technical Protocols Certificate of Analysis |
Related Products
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
